Royalty Pharma has withdrawn its request for a judicial review of the ruling that forces it to lapse its takeover offer for Elan under certain conditions, and has confirmed that its offer has now lapsed.
Elan shareholders yesterday narrowly approved the company's plan to buy back shares.
Elan's management has indicated that they would be agreeable to an offer in a range of $15 to $20, but only from a "high taxpaying suitor", wrote an...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team